No definition available.
Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, excluding all cancers (controls excluding all cancers)
C3_MACROGLOBULINEMIA_EXALLC
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
243 |
4. Check minimum number of eventsNone |
243 |
5. Include endpointsNone |
243 |
6. Filter based on genotype QC (FinnGen only) |
243 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 243 | 90 | 153 |
| Unadjusted period prevalence (%) | 0.05 | 0.03 | 0.07 |
| Median age at first event (years) | 67.64 | 65.39 | 68.96 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 125
- Matched controls
- 1249
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C88.0
ICD-10 Finland
Waldenström macroglobulinaemia
+∞
158.2
116
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
376.5
99.3
89
8
9761/3-C42.0
ICD-O-3
Waldenstrom macroglobulinemia of blood
+∞
98.3
81
*
XW000
NOMESCO Finland
Bone marrow biopsy
106.7
69.9
73
16
A04AA01
ATC
ondansetron; systemic, rectal
145.1
39.4
40
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
179.9
38.1
38
*
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
62.0
34.3
39
9
L03AA02
ATC
filgrastim; parenteral
409.6
32.4
31
*
H02AB02
ATC
dexamethasone; systemic
130.3
29.1
30
*
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
36.8
27.6
35
13
9671/3-C42.1
ICD-O-3
Lymphoplasmacytic lymphoma of bone marrow
+∞
27.1
25
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
279.1
23.5
23
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
264.4
22.4
22
*
JN4BD
NOMESCO Finland
Extensive body CT
16.9
22.2
36
29
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
16.9
21.6
35
28
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
249.9
21.3
21
*
390
Kela drug reimbursment
Ibrutinib
+∞
20.4
19
*
1512
Kela drug reimbursment
Ibrutinib
+∞
20.4
19
*
C83.01
ICD-10 Finland
Lymphoplasmacytic lymphoma
+∞
18.2
17
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
17.1
16
*
L01AA02
ATC
chlorambucil; oral
+∞
17.1
16
*
M04AA01
ATC
allopurinol; systemic
6.0
15.7
50
124
L03AA13
ATC
pegfilgrastim; parenteral
+∞
14.9
14
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.6
14.3
40
83
1XC02
NOMESCO Finland
NA
+∞
13.8
13
*
L01EL01
ATC
ibrutinib; oral
+∞
13.8
13
*
WW500
NOMESCO Finland
Blood transfusion
14.6
12.7
21
17
J05AB11
ATC
valaciclovir; oral
6.9
12.3
32
59
ZX120
NOMESCO Finland
Intravenous
7.9
12.0
28
44
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
11.6
11
*
C88.9
ICD-10 Finland
Malignant immunoproliferative disease, unspecified
+∞
11.6
11
*
L01XE27
ATC
[U] ibrutinib; oral
+∞
11.6
11
*
A04AA02
ATC
granisetron; systemic, transdermal
131.6
11.6
12
*
R50.9
ICD-10 Finland
Fever, unspecified
6.0
11.6
34
73
C90.0
ICD-10 Finland
Multiple myeloma
+∞
10.6
10
*
L01AA01
ATC
cyclophosphamide; systemic
+∞
10.6
10
*
JN4AD
NOMESCO Finland
Body CT examination
10.6
10.5
20
22
D64.9
ICD-10 Finland
Anaemia, unspecified
5.2
10.4
34
83
J05AB01
ATC
aciclovir; systemic
4.4
10.1
41
125
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
9.6
77
404
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
9.5
9
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
10.7
9.1
17
18
A03FA01
ATC
metoclopramide; systemic, rectal
4.6
8.6
31
83
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
+∞
8.4
8
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
84.9
7.5
8
*
N08.1*C88.0
ICD-10 Finland
Glomerular disorders in Waldenström's macroglobulinaemia
+∞
7.4
7
*
C83.9
ICD-10 Finland
Non-follicular (diffuse) lymphoma, unspecified
+∞
7.4
7
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
7.4
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.4
7
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.9
7.3
24
58
B03XA01
ATC
erythropoietin; parenteral
32.0
7.3
9
*
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
42.4
6.8
8
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
11.9
6.4
11
10
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
193
100
89.94
278.73
13.2
1.3
14.75
1.14
g/l
29.74
185
92
152
49
81.16
252.52
7.5
1.2
8.23
0.98
ratio
—
7
5
152
50
79.51
251.04
7.6
1.2
117.30
46.50
mg/l
3.02
126
41
152
51
77.92
249.57
7.5
1.2
29.43
35.03
mg/l
0.46
127
43
186
196
37.19
183.99
9.3
2.9
204.24
243.18
u/l
6.51
180
184
153
122
32.16
174.68
6.0
1.9
7.77
11.14
g/l
6.21
148
108
121
68
34.45
161.22
11.2
1.1
9.24
0.15
g/l
12.47
100
59
119
79
28.56
146.26
10.8
1.1
4.23
3.79
g/l
0.44
74
56
119
79
28.56
146.26
10.8
1.1
6.93
7.67
g/l
2.33
85
60
119
79
28.56
146.26
10.8
1.1
—
—
—
0
0
110
76
25.62
131.65
11.4
1.1
2.92
3.13
g/l
0.87
76
57
107
71
26.14
130.49
11.1
1.1
16.02
10.56
g/l
4.25
85
59
87
50
26.55
112.28
2.4
1.6
—
—
—
0
0
102
9
193.43
103.74
1.7
1.7
3.48
3.49
mg/l
—
97
9
146
262
12.45
90.72
5.5
2.2
1.61
1.71
%
0.48
137
237
127
198
12.34
87.91
5.6
2.3
62.77
65.63
e9/l
0.37
102
156
81
66
17.91
86.65
11.9
1.1
37.93
37.88
g/l
0.02
70
53
90
94
14.62
82.60
2.7
1.8
1.38
1.45
g/l
0.28
80
83
142
314
9.47
70.89
4.3
1.2
1.48
2.92
g/l
5.87
127
179
157
528
6.58
47.05
6.4
2.6
1914.95
11034.07
umol/l
2.12
148
459
197
831
8.24
45.35
14.4
5.1
53.55
58.14
%
5.38
192
767
101
238
6.55
44.35
9.4
4.8
1.05
1.01
mmol/l
0.68
94
211
35
21
19.30
42.69
2.2
1.5
—
—
—
0
0
208
981
8.78
40.56
25.9
5.9
3.46
4.36
e9/l
9.48
195
850
187
815
6.62
39.41
8.9
3.5
32.93
35.10
g/l
4.87
182
751
202
950
7.68
38.76
18.5
5.6
1.22
1.21
mmol/l
0.55
168
816
28
14
22.47
36.85
1.6
1.7
—
—
—
0
0
28
14
22.47
36.85
1.6
1.7
—
—
—
0
0
37
35
12.29
34.85
2.7
1.5
—
—
—
0
0
32
26
14.02
33.04
2.8
1.5
—
—
—
0
0
23
10
25.30
31.83
1.7
2.1
—
—
—
0
0
35
35
11.51
31.69
2.9
1.5
—
—
—
0
0
183
877
5.40
31.65
16.3
5.2
1.22
1.21
mmol/l
1.41
178
775
92
270
4.87
29.98
4.0
2.4
24.70
23.31
%
0.34
85
236
93
281
4.74
29.11
5.0
3.0
0.80
0.82
mmol/l
0.89
88
258
129
509
4.27
28.03
2.9
2.2
3.07
3.11
mg/l
0.05
113
428
23
15
16.83
26.58
2.4
1.4
—
—
—
0
0
23
17
14.84
24.85
2.4
1.4
—
—
—
0
0
26
25
11.53
23.98
2.7
2.2
33.04
33.68
pg
0.28
26
25
28
31
10.08
23.42
1.4
1.3
—
—
—
0
0
153
746
3.84
23.16
4.8
2.7
206.40
135.47
ug/l
1.80
147
680
24
22
12.00
22.79
1.7
1.2
—
—
—
0
0
91
317
3.99
22.78
3.1
1.9
31.59
29.77
s
1.42
85
303
93
337
3.85
21.86
2.9
1.8
—
—
—
0
0
132
604
3.60
21.64
5.2
2.1
2.35
2.35
mmol/l
0.01
116
500
18
11
17.59
21.32
2.7
1.1
—
—
—
0
0
18
11
17.59
21.32
2.7
1.1
—
—
—
0
0
18
11
17.59
21.32
2.7
1.1
—
—
—
0
0
52
124
5.06
21.23
2.8
1.5
—
—
—
0
0
22
21
11.42
20.29
1.9
1.8
—
—
—
0
0
18
0
+∞
19.00
5.3
0.0
—
—
—
0
0
25
32
8.59
18.63
2.0
1.3
—
—
—
0
0
16
11
15.50
17.78
2.1
2.8
37.60
55.00
%
—
5
5
21
23
9.90
17.57
2.3
1.4
—
—
—
0
0
22
27
8.86
16.91
2.0
1.3
—
—
—
0
0
143
768
3.09
16.62
7.0
3.6
—
—
—
0
0
45
116
4.53
16.52
2.8
1.4
2.80
5.36
ug/l
0.52
33
92
36
77
5.31
16.48
2.9
3.5
—
—
—
0
0
20
23
9.39
16.12
2.0
1.5
—
—
—
0
0
20
25
8.63
15.11
2.0
1.4
—
—
—
0
0
19
23
8.88
14.70
1.5
1.1
—
—
—
0
0
17
19
9.55
13.94
2.7
1.7
—
—
—
0
0
94
436
2.89
13.69
1.9
1.8
1157.77
1193.05
nmol/l
0.12
73
336
21
32
7.09
13.42
4.9
1.6
2.77
4.56
e9/l
2.73
21
32
87
392
2.90
13.31
4.9
2.1
—
—
—
0
0
21
33
6.87
13.05
6.2
2.2
51.33
59.76
%
1.26
21
33
14
13
11.37
12.97
1.1
1.2
—
—
—
0
0
14
13
11.37
12.97
1.4
1.2
—
—
—
0
0
24
44
5.94
12.87
1.8
1.4
—
—
—
0
0
124
688
2.64
12.44
4.7
3.1
—
—
—
0
0
105
545
2.63
11.97
2.1
1.5
21.99
20.82
nmol/l
0.29
93
461
61
242
3.03
11.57
2.5
1.7
—
—
—
0
0
198
1416
3.15
11.54
8.2
4.2
54.34
12.45
mm/h
30.36
188
1285
14
16
9.22
11.22
3.0
1.1
—
—
—
0
0
60
240
2.99
11.19
2.6
1.8
—
—
—
0
0
14
17
8.68
10.72
3.0
1.1
—
—
—
0
0
14
17
8.68
10.72
3.0
1.1
—
—
—
0
0
14
17
8.68
10.72
3.0
1.1
—
—
—
0
0
14
17
8.68
10.72
2.9
1.1
—
—
—
0
0
14
17
8.68
10.72
3.0
1.1
—
—
—
0
0
14
6
24.63
10.36
3.1
1.2
—
—
—
0
0
14
6
24.63
10.36
3.1
1.2
—
—
—
0
0
14
6
24.63
10.36
3.1
1.2
—
—
—
0
0
14
6
24.63
10.36
3.1
1.2
—
—
—
0
0
141
891
2.39
9.96
2.6
2.0
95.34
92.11
pmol/l
0.28
89
468
13
6
22.77
9.45
3.3
1.0
—
—
—
0
0
13
6
22.77
9.45
3.3
1.0
—
—
—
0
0
13
6
22.77
9.45
3.3
1.0
—
—
—
0
0
23
54
4.60
9.34
2.0
1.2
—
—
—
0
0
21
48
4.69
8.80
1.4
1.2
—
—
—
0
0
14
22
6.69
8.62
1.5
1.1
313.00
246.40
u/ml
—
9
10
13
9
15.17
8.30
2.3
1.8
—
—
—
0
0
14
23
6.40
8.27
1.5
1.5
—
—
—
0
0
10
11
9.44
8.14
1.0
1.0
—
—
—
0
0
94
534
2.24
8.12
4.9
2.8
0.85
0.49
e6/l
0.46
78
386
117
733
2.15
7.84
3.6
3.3
1541.43
1516.61
ng/l
0.03
102
625
72
371
2.34
7.80
4.0
2.2
2.53
2.44
mmol/l
4.73
62
317
18
42
4.55
7.35
1.6
1.5
—
—
—
0
0
116
738
2.09
7.33
2.7
2.2
85.13
78.09
nmol/l
1.39
105
635
12
19
6.59
7.31
5.1
1.9
—
—
—
0
0
11
7
16.37
7.30
2.4
1.3
—
—
—
0
0
11
7
16.37
7.30
2.5
2.0
—
—
—
0
0
11
7
16.37
7.30
2.5
2.0
—
—
—
0
0
38
152
2.78
6.93
15.8
2.6
1.24
1.22
mmol/l
1.43
38
125
26
84
3.35
6.82
3.4
1.6
—
—
—
0
0
10
14
7.41
6.75
3.5
1.6
—
—
—
0
0
74
407
2.18
6.73
2.3
1.7
2.39
1.22
mg/l
0.44
61
319
11
9
12.73
6.65
4.0
1.2
—
—
—
0
0
10
7
14.82
6.45
2.4
1.3
—
—
—
0
0
6
0
+∞
6.27
1.0
0.0
—
—
—
0
0
45
208
2.43
6.11
5.3
3.2
—
—
—
0
0
36
151
2.62
5.97
4.6
3.7
93.63
82.25
ng/l
0.22
30
131
9
6
15.50
5.95
3.8
1.8
—
—
—
0
0
10
9
11.52
5.85
1.3
1.0
—
—
—
0
0
10
17
6.09
5.67
1.1
1.1
—
—
—
0
0
32
132
2.64
5.48
2.1
1.6
—
—
—
0
0
35
151
2.54
5.48
2.5
2.0
0.15
0.20
g/l
2.50
29
132
8
5
16.46
5.44
2.4
1.0
—
—
—
0
0
8
5
16.46
5.44
2.4
1.0
—
—
—
0
0
15
39
4.03
5.35
2.9
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
70
3.19
5.24
4.9
2.6
0.28
0.38
u/ml
—
8
34
55
298
2.09
5.07
1.4
1.3
71.02
29.66
iu/ml
0.41
12
84
92
607
1.83
4.73
3.6
2.2
60.72
58.44
u/l
0.16
87
557
30
130
2.49
4.65
1.7
1.4
—
—
—
0
0
58
337
1.95
4.37
4.2
2.6
1.90
1.21
e6/l
0.33
40
190
54
308
1.97
4.29
4.6
2.9
2.05
2.33
e6/l
0.12
36
162
48
274
1.94
3.78
1.3
1.3
0.80
12.02
u/ml
2.01
13
96
32
159
2.17
3.65
3.9
2.0
30.44
33.28
u/l
0.21
25
129
9
17
5.45
3.54
1.2
1.1
—
—
—
0
0
9
17
5.45
3.54
1.2
1.1
—
—
—
0
0
15
52
3.01
3.53
1.4
2.6
—
—
—
0
0
212
1871
2.04
3.48
45.3
13.9
22.48
24.26
mg/l
0.43
201
1448
119
900
1.63
3.47
3.1
2.3
—
—
—
0
0
8
14
5.87
3.37
1.6
1.0
—
—
—
0
0
6
7
8.75
3.28
1.7
1.1
—
—
—
0
0
6
7
8.75
3.28
4.8
2.9
13.33
13.24
%
—
6
7
12
38
3.27
3.26
1.9
1.3
—
—
—
0
0
12
38
3.27
3.26
1.9
1.3
—
—
—
0
0
121
933
1.59
3.17
4.6
3.8
0.00
0.02
estimate
0.50
27
145
9
20
4.63
3.14
1.8
1.2
—
—
—
0
0
118
911
1.57
3.03
4.7
3.8
0.00
0.00
estimate
0.00
28
152
18
77
2.44
2.89
2.5
1.6
—
—
—
0
0
118
918
1.55
2.89
6.4
5.2
0.00
0.00
estimate
0.00
28
149
65
441
1.65
2.83
3.5
4.1
300.02
347.54
ng/l
0.08
54
374
9
23
4.02
2.80
1.2
1.1
—
—
—
0
0
9
23
4.02
2.80
6.9
4.2
—
—
—
0
0
12
43
2.88
2.68
1.5
1.6
12.75
39.76
u/ml
0.67
12
43
6
11
5.56
2.56
1.0
1.3
—
—
—
0
0
31
176
1.87
2.48
11.3
6.1
1.14
1.47
mmol/l
2.01
31
167
29
161
1.91
2.48
1.4
1.8
1.80
1.73
%
0.14
22
134
138
1136
1.50
2.46
4.2
3.1
60.61
53.25
u/l
0.40
127
1039
27
148
1.93
2.40
2.8
2.0
38.50
58.02
ml/min/173m2
2.82
12
57
5
8
6.35
2.38
1.0
1.0
—
—
—
0
0
6
13
4.70
2.28
1.7
1.2
—
—
—
0
0
5
9
5.64
2.22
7.0
1.4
153.20
223.56
u/l
—
5
9
8
24
3.41
2.20
1.1
1.1
—
—
—
0
0
185
1639
1.54
2.16
39.3
15.1
34.13
39.37
%
6.19
115
1035
161
1389
1.47
2.12
3.6
3.6
14.84
15.06
pmol/l
0.52
140
1234
110
884
1.45
2.11
5.5
4.1
41.69
46.47
ng/l
0.20
88
675
7
23
3.10
1.81
1.3
1.0
—
—
—
0
0
38
252
1.60
1.80
11.1
6.7
0.89
1.59
mmol/l
0.64
32
195
10
41
2.50
1.78
2.1
1.6
—
—
—
0
0
8
31
2.63
1.67
1.3
1.1
—
—
—
0
0
19
107
1.84
1.60
15.4
8.5
24.11
24.87
mmol/l
0.60
19
94
6
20
3.05
1.59
1.7
1.4
92.92
72.47
pmol/l
—
6
20
27
170
1.66
1.57
2.3
1.6
321.85
365.28
nmol/l
0.69
27
153
5
19
2.66
1.22
1.2
1.0
39.40
35.56
ng/l
—
5
13
5
19
2.66
1.22
1.2
1.0
850.20
572.79
ng/l
—
5
14
5
19
2.66
1.22
1.2
1.0
301.00
267.21
ng/l
—
5
14
111
972
1.26
1.01
4.4
4.0
1.91
2.08
ug/l
0.20
95
858
57
459
1.32
0.99
1.5
1.8
494.71
422.60
pmol/l
1.04
45
372
30
218
1.43
0.97
6.7
3.2
2.20
2.15
mmol/l
0.02
24
179
186
1736
1.30
0.97
4.4
4.5
1.94
1.96
mu/l
0.08
171
1550
210
1998
1.38
0.92
46.2
16.7
92.33
83.25
umol/l
1.05
210
1998
8
47
1.73
0.81
1.4
1.1
—
—
—
0
0
43
527
0.78
0.76
1.5
1.7
1.31
1.35
mmol/l
0.12
38
425
6
110
0.53
0.74
1.7
1.9
—
—
—
0
0
175
1845
0.82
0.69
5.7
6.8
37.90
41.06
mmol/mol
7.67
159
1692
82
720
1.21
0.68
5.2
4.0
—
—
—
0
0
5
28
1.80
0.66
2.4
1.0
—
—
—
0
0
178
1868
0.82
0.63
3.9
5.0
1.39
1.43
mmol/l
0.68
160
1687
8
50
1.62
0.62
1.4
1.2
—
—
—
0
0
173
1815
0.84
0.58
3.8
4.5
1.13
1.28
mmol/l
2.50
153
1626
186
1939
0.83
0.58
4.4
5.7
2.33
2.59
mmol/l
4.05
170
1752
181
1888
0.84
0.54
3.9
5.0
4.16
4.45
mmol/l
2.98
165
1714
10
67
1.51
0.50
1.3
1.3
—
—
—
0
0
184
1764
1.18
0.48
36.7
12.8
73.81
73.65
ml/min/173m2
0.04
166
1415
5
81
0.61
0.46
1.0
1.2
—
99.05
—
0
28
7
50
1.41
0.45
1.1
1.2
—
—
—
0
0
7
50
1.41
0.45
1.1
1.2
—
—
—
0
0
5
33
1.53
0.41
1.0
1.2
—
—
—
0
0
60
536
1.16
0.41
2.9
2.7
0.61
0.76
ug/l
1.36
42
368
8
60
1.34
0.40
1.4
1.4
—
—
—
0
0
57
509
1.16
0.39
5.7
3.9
0.00
0.02
estimate
0.50
23
146
212
2067
1.20
0.38
60.8
20.3
3.95
4.50
e12/l
30.07
206
1990
17
139
1.24
0.30
1.2
1.3
—
—
—
0
0
17
139
1.24
0.30
1.8
2.4
14.07
14.99
nmol/l
0.24
17
124
83
774
1.11
0.29
3.9
3.9
20.59
24.47
%
1.47
44
366
37
329
1.15
0.28
40.1
25.6
1.07
1.30
inr
—
6
44
30
265
1.15
0.25
9.6
7.7
—
—
—
0
0
21
180
1.18
0.24
1.4
1.3
—
—
—
0
0
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
5
38
1.32
0.23
3.8
2.4
105.60
105.71
mmol/l
—
5
38
30
267
1.14
0.23
4.6
4.9
32.95
31.18
%
0.35
21
174
187
1898
0.94
0.13
4.9
5.1
5.93
6.15
mmol/l
2.22
166
1701
25
229
1.10
0.13
1.9
2.9
8.11
8.38
ug/l
0.02
20
200
8
78
1.03
0.07
1.0
1.0
—
—
—
0
0
13
120
1.09
0.05
4.6
2.2
1.07
1.11
%
0.08
13
120
72
733
0.97
0.04
4.0
4.1
15.54
7.99
mg/mmol
0.52
48
462
0
5
0.00
0.00
0.0
1.2
—
0.59
—
0
5
0
8
0.00
0.00
0.0
3.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
1.32
—
0
5
0
8
0.00
0.00
0.0
3.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
69.00
—
0
7
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_MACROGLOBULINEMIA_EXALLC – Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, excluding all cancers (controls excluding all cancers)
GWS hits: 3
This endpoint is excluded (different definition than used in FinnGen).